Across TCGA pan-cancer cohorts, PRPSAP1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRPSAP1 data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRPSAP1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRPSAP1 expression acts as an unfavorable survival marker.
HNSC, KIRC, and CESC are the cancer types where PRPSAP1 Mutation most reproducibly stratifies survival.